The NOAH-AFNET 6 trial, unveiled during the European Society of Cardiology Congress 2023, sought to investigate whether edoxaban could effectively prevent strokes or cardiovascular (CV) fatalities among patients experiencing atrial high rate episodes. The primary endpoint of the study encompassed a composite of CV death, stroke, or systemic embolism. Meanwhile, the safety outcome was a composite of mortality from any cause or the occurrence of major bleeding events.
After a median follow-up period of 21 months, the trial’s trajectory was abruptly halted due to emerging concerns about its futility and safety. Regrettably, edoxaban demonstrated no significant reduction in the incidence of the primary endpoint when compared to a placebo. Furthermore, the safety analysis revealed a higher frequency of adverse events associated with edoxaban as opposed to the placebo.
Learn more about the interesting studies presented at ESC Congress 2023.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
